Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

Executive Summary

Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.

You may also be interested in...



Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns

REMS with provider and pharmacy certification could help address hepatotoxicity worries for the tenosynovial giant cell tumor treatment, but Daiichi likely also will face clinical benefit questions during advisory committee review.

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel